METiS Therapeutics, a China-US biotech startup that integrates drug discovery and delivery with artificial intelligence (AI), announced on Wednesday the completion of two funding rounds at a total of $150 million.
The two funding rounds were jointly led by PICC Capital, the main alternative investment platform of China’s government-controlled insurer PICC Group, and China Life Private Equity Investment, a private equity (PE) arm of Beijing-based life insurer China Life Insurance.
